Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emile E Voest

Showing results (11-20 of 236) with videos related to

Pageof 24
Sort By:
Blood|May 29, 2004
Do antiangiogenic protein fragments have amyloid properties?Martijn F B G Gebbink, Emile E Voest, Arie Reijerkerk
Biochimica Et Biophysica Acta|February 27, 2004
Stimulation of angiogenesis by Ras proteinsOnno Kranenburg, Martijn F B G Gebbink, Emile E Voest
Digestive Surgery|September 22, 2005
VEGF as a target of therapy in gastrointestinal oncologyMaartje Los, Emile E Voest, Inne H M Borel Rinkes
Nature Reviews. Cancer|November 25, 2010
Shared and separate functions of polo-like kinases and aurora kinases in cancerSusanne M A Lens, Emile E Voest, René H Medema
Expert Opinion on Emerging Drugs|May 21, 2009
Emerging drugs for esophageal cancerMarjolein Y V Homs, Emile E Voest, Peter D Siersema
Journal of the National Cancer Institute|February 8, 2007
Re: Tissue banks trigger worry about ownership issuesPaul J van Diest, J Alain Kummer, Emile E Voest
Current Clinical Pharmacology|August 12, 2008
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathwayJeanine M Roodhart, Marlies H Langenberg, Els Witteveen, et al.
JAMA Oncology|August 5, 2016
Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A ReviewKrijn K Dijkstra, Paula Voabil, Ton N Schumacher, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 13, 2014
[Drug research in oncology; advances in the genome era]Sander Bins, Jan H M Schellens, Emile E Voest, et al.
Cell Chemical Biology|August 1, 2017
Tumor Organoids as a Pre-clinical Cancer Model for Drug DiscoveryFleur Weeber, Salo N Ooft, Krijn K Dijkstra, et al.
Pageof 24

Showing results (11-20 of 236) with videos related to

Sort By:
Pageof 24
Blood|May 29, 2004
Do antiangiogenic protein fragments have amyloid properties?Martijn F B G Gebbink, Emile E Voest, Arie Reijerkerk
Biochimica Et Biophysica Acta|February 27, 2004
Stimulation of angiogenesis by Ras proteinsOnno Kranenburg, Martijn F B G Gebbink, Emile E Voest
Digestive Surgery|September 22, 2005
VEGF as a target of therapy in gastrointestinal oncologyMaartje Los, Emile E Voest, Inne H M Borel Rinkes
Nature Reviews. Cancer|November 25, 2010
Shared and separate functions of polo-like kinases and aurora kinases in cancerSusanne M A Lens, Emile E Voest, René H Medema
Expert Opinion on Emerging Drugs|May 21, 2009
Emerging drugs for esophageal cancerMarjolein Y V Homs, Emile E Voest, Peter D Siersema
Journal of the National Cancer Institute|February 8, 2007
Re: Tissue banks trigger worry about ownership issuesPaul J van Diest, J Alain Kummer, Emile E Voest
Current Clinical Pharmacology|August 12, 2008
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathwayJeanine M Roodhart, Marlies H Langenberg, Els Witteveen, et al.
JAMA Oncology|August 5, 2016
Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A ReviewKrijn K Dijkstra, Paula Voabil, Ton N Schumacher, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 13, 2014
[Drug research in oncology; advances in the genome era]Sander Bins, Jan H M Schellens, Emile E Voest, et al.
Cell Chemical Biology|August 1, 2017
Tumor Organoids as a Pre-clinical Cancer Model for Drug DiscoveryFleur Weeber, Salo N Ooft, Krijn K Dijkstra, et al.
Pageof 24